The Lasker Foundation Announces 2024 Award Recipients Recognizing Pioneers in Sleep Science, Hematology and Patient Advocacy
The Albert and Mary Lasker Foundation has officially announced the recipients of its prestigious 2024 Lasker Awards, an annual recognition that carries significant weight in the global scientific community. Frequently referred to as "America’s Nobel Prizes" due to the high correlation between Lasker recipients and subsequent Nobel Prize wins, this year’s honors highlight transformative advancements in the mechanics of sleep, the clinical management of rare genetic disorders, and the profound impact of public advocacy on neurodegenerative research.
The awards, which comprise three distinct categories—Basic Medical Research, Clinical Medical Research, and Public Service—underscore a commitment to both laboratory discovery and the real-world application of medical science. By honoring those who bridge the gap between bench science and patient care, the Lasker Foundation continues to shape the trajectory of modern medicine.
The Frontiers of Sleep Research
The 2024 Albert Lasker Basic Medical Research Award was presented to Masashi Yanagisawa of the University of Tsukuba for his seminal discovery of orexins, the neuropeptides that regulate the sleep-wake cycle.
In the late 1990s, the scientific understanding of sleep was largely focused on the chemical neurotransmitters that signal the brain to "shut down." However, Dr. Yanagisawa’s team identified that orexins—also known as hypocretins—act as the "on" switch for wakefulness. This discovery fundamentally altered the field, moving the focus from sleep as a passive state to an active, regulated neurological process.
The implications of this work are vast. Patients suffering from narcolepsy, a chronic sleep disorder characterized by an inability to remain awake, were found to have a significant deficiency in orexin-producing neurons. This discovery paved the way for the development of orexin receptor antagonists, a new class of medications that help patients maintain healthy sleep patterns. According to data from the National Institutes of Health (NIH), sleep disorders currently affect an estimated 50 to 70 million Americans, leading to a significant public health burden. The Lasker Foundation’s recognition of Dr. Yanagisawa serves to emphasize that sleep science is no longer a peripheral area of study but a critical component of cardiovascular, metabolic, and neurological health.
Breakthroughs in Hematology: Treating Hemophilia
The 2024 Lasker-DeBakey Clinical Medical Research Award was conferred upon researchers who developed a transformative treatment for hemophilia B. This honor recognizes the clinical evolution from managing life-threatening bleeding episodes to potentially curative gene therapy.
Hemophilia B is an inherited bleeding disorder caused by a deficiency in coagulation factor IX. For decades, the standard of care involved frequent, prophylactic infusions of recombinant factor IX, which placed a heavy burden on patients and healthcare systems. The winning researchers pioneered the use of adeno-associated virus (AAV) vectors to deliver a functional copy of the factor IX gene directly to liver cells.
Clinical trial data presented in conjunction with the award highlighted that a single infusion of this gene therapy could enable the patient’s own liver to produce sufficient levels of the clotting factor, effectively eliminating the need for regular injections for years at a time. This represents a paradigm shift in hematology. The transition from "replacement therapy" to "functional cure" signifies one of the most successful applications of gene therapy to date, demonstrating that the scientific community is now capable of addressing the root genetic cause of complex blood disorders.
The Lasker Award for Public Service: Michael J. Fox
The Lasker-Bloomberg Public Service Award was presented to actor and activist Michael J. Fox. Since his diagnosis with young-onset Parkinson’s disease in 1991, Fox has transitioned from a celebrated entertainer to one of the most influential figures in biomedical research advocacy.
Through the Michael J. Fox Foundation for Parkinson’s Research (MJFF), established in 2000, Fox has spearheaded a unique funding model that emphasizes high-risk, high-reward research. To date, the MJFF has funded over $2 billion in research, making it the largest non-profit funder of Parkinson’s drug development in the world.
The foundation’s approach has been credited with accelerating the development of biomarkers for the disease, most notably the discovery of the alpha-synuclein seed amplification assay (SAA). This test allows for the detection of Parkinson’s pathology in living patients, a feat previously only possible through post-mortem brain examination. By prioritizing patient-centric data collection and open-access research, Fox has fostered an environment where academic, industrial, and patient interests intersect to speed the path toward a cure.
A Historical Context of the Lasker Awards
Established in 1945 by Albert and Mary Lasker, the foundation was created with the intent to spark public interest in medical research. In the post-World War II era, the Laskers recognized that the federal government needed to increase its investment in the National Institutes of Health. Their advocacy efforts, combined with the prestige of the awards, helped usher in a "Golden Age" of biomedical research in the United States.
Historically, the Lasker Awards have been a bellwether for scientific excellence. Over 95 Lasker winners have gone on to receive a Nobel Prize. The foundation’s committees, comprised of esteemed scientists and physicians, utilize a rigorous selection process that involves international nominations and extensive peer review. The awards are typically presented in New York City, serving as a high-profile platform to discuss current scientific hurdles and the necessity of sustained funding.
Impact and Future Implications
The selection of these specific honorees sends a clear signal about the current priorities in medical research.
- Precision Medicine and Neurobiology: The recognition of sleep science underscores the growing importance of the "brain-body" connection. As research links poor sleep to conditions such as Alzheimer’s disease and hypertension, the fundamental understanding of how the brain regulates rest is becoming a cornerstone of preventative medicine.
- The Maturation of Gene Therapy: The hemophilia award validates the long-term investment in viral vector technology. After years of setbacks in the 1990s and early 2000s, the field of gene therapy has finally reached a stage of clinical maturity, suggesting that similar cures may be on the horizon for other monogenic disorders, such as sickle cell disease and muscular dystrophy.
- The Power of Patient-Driven Science: The awarding of the Public Service prize to Michael J. Fox reflects a broader trend in medical research: the democratization of discovery. Modern research is increasingly driven by patient advocacy groups that provide not only capital but also the strategic direction for drug development pipelines. This shift ensures that research is aligned with the lived experiences and urgent needs of those affected by disease.
Official Responses and Industry Outlook
In response to the announcement, the Lasker Foundation’s leadership emphasized that the 2024 winners embody the spirit of persistence. "Science is not a linear process," a spokesperson for the Foundation noted. "It requires decades of curiosity, the courage to challenge established dogmas, and the support of a public that understands the value of investment in the unknown."
The pharmaceutical and biotech sectors have also welcomed the recognition. Industry analysts note that the Lasker Awards provide a "seal of approval" that often stimulates further venture capital and government interest in the fields of the winning discoveries. For the hemophilia research community, the award is seen as a vindication of the collaborative model between academic labs and commercial biotech, which proved essential in bringing the gene therapy from a theoretical concept to an FDA-approved treatment.
As the scientific community looks toward 2025, the themes established by this year’s Lasker Awards—neuroplasticity, genetic precision, and patient-led innovation—are expected to define the primary research agendas for the coming decade. Through these awards, the foundation continues its mission of ensuring that the most profound contributions to human health are not only recognized but are integrated into the global conversation on scientific progress.
